You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
NEW YORK – Natera's personalized ctDNA assay technology has shown new potential as a tool to assess the efficacy of breast cancer neoadjuvant chemotherapy and potentially guide decisions regarding further adjuvant treatment after surgery.
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.